Ocuphire Pharma Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
IRD$4.20+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
None
OCUPHIRE PHARMA, INC.
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
|---|
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 110 |
|---|---|
| Balance Sheets | 111 |
| Statements of Comprehensive (Loss) Income | 112 |
| Statements of Changes in Stockholders’ Equity | 113 |
| Statements of Cash Flows | 114 |
| Notes to Financial Statements | 115-135 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.